Sirolimus-based Immunosuppression Treatment Regimen for Liver Transplantation
Status:
Not yet recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, randomized, controlled clinical trial, in order to compare
sirolimus-based (tacrolimus-free) versus tacrolimus-based (sirolimus-free) immunosuppression
regimen for Hepatocellular Carcinoma (HCC) patients after liver transplantation.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Southern Medical University, China
Collaborators:
First Affiliated Hospital, Sun Yat-Sen University Nanfang Hospital of Southern Medical University